The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Interleukin-2

This is a "connection" page, showing publications Thomas F. Gajewski has written about Interleukin-2.
Connection Strength

1.798
  1. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8.
    View in: PubMed
    Score: 0.276
  2. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
    View in: PubMed
    Score: 0.226
  3. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
    View in: PubMed
    Score: 0.186
  4. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400.
    View in: PubMed
    Score: 0.135
  5. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
    View in: PubMed
    Score: 0.101
  6. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931.
    View in: PubMed
    Score: 0.093
  7. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989 Jul 01; 143(1):15-22.
    View in: PubMed
    Score: 0.080
  8. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.063
  9. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
    View in: PubMed
    Score: 0.063
  10. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
    View in: PubMed
    Score: 0.063
  11. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7.
    View in: PubMed
    Score: 0.060
  12. Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9351-6.
    View in: PubMed
    Score: 0.056
  13. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol. 2004 Feb; 24(4):1628-39.
    View in: PubMed
    Score: 0.055
  14. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.
    View in: PubMed
    Score: 0.049
  15. Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl). 1996 Nov; 74(11):673-83.
    View in: PubMed
    Score: 0.033
  16. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72.
    View in: PubMed
    Score: 0.031
  17. "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91.
    View in: PubMed
    Score: 0.027
  18. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42.
    View in: PubMed
    Score: 0.027
  19. Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones. Eur J Immunol. 1992 Sep; 22(9):2359-65.
    View in: PubMed
    Score: 0.025
  20. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.021
  21. Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol. 1990 Jun 01; 144(11):4110-20.
    View in: PubMed
    Score: 0.021
  22. Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct; 111:79-110.
    View in: PubMed
    Score: 0.020
  23. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15; 140(12):4245-52.
    View in: PubMed
    Score: 0.019
  24. Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. J Immunol. 1987 Dec 15; 139(12):3942-8.
    View in: PubMed
    Score: 0.018
  25. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol. 2006 May; 174(1-2):74-81.
    View in: PubMed
    Score: 0.016
  26. An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30.
    View in: PubMed
    Score: 0.016
  27. Blocked Ras activation in anergic CD4+ T cells. Science. 1996 Mar 01; 271(5253):1276-8.
    View in: PubMed
    Score: 0.008
  28. Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol. 1993 Jul 01; 151(1):38-47.
    View in: PubMed
    Score: 0.007
  29. Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.